Page last updated: 2024-10-25

desipramine and Acute Confusional Senile Dementia

desipramine has been researched along with Acute Confusional Senile Dementia in 33 studies

Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.

Research Excerpts

ExcerptRelevanceReference
"59 moderate Alzheimer patients with major depressive disorder were randomly divided into 3 groups (sertraline, venlafaxine and desipramine), treated for 12 weeks (150 mg maximum dose) and assessed by the Hamilton Depression Test (HRSD), the Mini Mental State Examination (MMSE) and the Barthel index at the week 0 and the 2(nd), 4(th), 8(th), 12(th) weeks thereafter."2.79Comparison of sertraline, venlafaxine and desipramine effects on depression, cognition and the daily living activities in Alzheimer patients. ( Abdollahian, E; Azarpazhooh, A; Haghighi, MB; Mokhber, N; Saghebi, A; Samadi, R; Soltanifar, A, 2014)
"Alzheimer's disease is the most common cause of dementia."1.42In Vitro Inhibitory Effects of 8-O-Demethylmaritidine and Undulatine on Acetylcholinesterase and Their Predicted Penetration across the Blood-Brain Barrier. ( Cahlíková, L; Chlebek, J; Hošt'álková, A; Opletal, L; Pérez, DI; Šafratová, M; Štěpánková, Š, 2015)

Research

Studies (33)

TimeframeStudies, this research(%)All Research%
pre-19901 (3.03)18.7374
1990's2 (6.06)18.2507
2000's3 (9.09)29.6817
2010's23 (69.70)24.3611
2020's4 (12.12)2.80

Authors

AuthorsStudies
Shutske, GM1
Pierrat, FA1
Kapples, KJ1
Cornfeldt, ML1
Szewczak, MR1
Huger, FP1
Bores, GM1
Haroutunian, V1
Davis, KL1
McKenna, MT1
Proctor, GR1
Young, LC1
Harvey, AL1
Marco-Contelles, J1
León, R3
de los Ríos, C1
Samadi, A1
Bartolini, M3
Andrisano, V4
Huertas, O2
Barril, X1
Luque, FJ3
Rodríguez-Franco, MI6
López, B3
López, MG4
García, AG3
Carreiras, Mdo C1
Villarroya, M4
Camps, P1
Formosa, X1
Galdeano, C1
Muñoz-Torrero, D3
Ramírez, L1
Gómez, E1
Isambert, N1
Lavilla, R2
Badia, A1
Clos, MV2
Mancini, F2
Arce, MP4
Dafni, T1
González-Muñoz, GC2
Pérez, C4
Conde, S3
Romero, A1
del Barrio, L1
Martín-de-Saavedra, MD1
Egea, J2
Tang, H3
Zhao, LZ1
Zhao, HT2
Huang, SL2
Zhong, SM2
Qin, JK1
Chen, ZF2
Huang, ZS2
Liang, H2
Chiriano, G1
De Simone, A2
Perez, DI2
Cavalli, A1
Bolognesi, ML1
Legname, G1
Martinez, A1
Carloni, P1
Roberti, M1
Wang, ZY1
Sun, Y2
Chen, J1
Chen, X1
Huang, L3
Li, X6
Di Pietro, O1
Pérez-Areales, FJ2
Juárez-Jiménez, J1
Espargaró, A2
Pérez, B3
Sabaté, R2
Miao, H1
Meng, F1
Cahlíková, L1
Štěpánková, Š1
Chlebek, J1
Šafratová, M1
Hošt'álková, A1
Opletal, L1
Wang, H2
Lu, Z1
Zheng, X1
Ni, W1
Zhu, J2
Fu, Y2
Lian, F1
Zhang, N1
Li, J4
Zhang, H2
Mao, F2
Wang, B1
Wang, Z1
Chen, H1
Lu, CJ1
Wei, S1
Chen, W1
Qin, J1
Huangli, Y1
Wang, L1
Shen, Y1
Xia, CL1
Wang, N1
Guo, QL1
Liu, ZQ1
Wu, JQ1
Ou, TM1
Tan, JH1
Wang, HG1
Li, D1
Monjas, L1
Gil, C1
Hepnarova, V1
Korabecny, J1
Matouskova, L1
Jost, P1
Muckova, L1
Hrabinova, M1
Vykoukalova, N1
Kerhartova, M1
Kucera, T1
Dolezal, R1
Nepovimova, E1
Spilovska, K1
Mezeiova, E1
Pham, NL1
Jun, D1
Staud, F1
Kaping, D1
Kuca, K1
Soukup, O1
Reis, J1
Cagide, F1
Valencia, ME1
Teixeira, J1
Bagetta, D1
Uriarte, E1
Oliveira, PJ1
Ortuso, F1
Alcaro, S1
Borges, F1
Hu, J1
Pan, T1
An, B1
Li, Z1
Turcu, AL2
Barniol-Xicota, M1
Pont, C1
Pivetta, D1
Sureda, FX2
Vázquez, S2
Jiang, X2
Zhou, J1
Wang, Y3
Chen, L1
Duan, Y1
Huang, J2
Liu, C2
Chen, Y2
Liu, W2
Sun, H2
Feng, F2
Qu, W1
Xing, C1
Lyu, W1
Wang, S1
Li, Q1
Chen, T1
Huang, Y1
Gong, Q1
Xu, Y1
You, H1
Zhang, D2
Companys-Alemany, J1
Phillips, MB1
Patel, DS1
Griñán-Ferré, C1
Loza, MI1
Brea, JM1
Soto, D1
Kurnikova, MG1
Johnson, JW1
Pallàs, M1
Mokhber, N1
Abdollahian, E1
Soltanifar, A1
Samadi, R1
Saghebi, A1
Haghighi, MB1
Azarpazhooh, A1
Dias, IH1
Mistry, J1
Fell, S1
Reis, A1
Spickett, CM1
Polidori, MC1
Lip, GY1
Griffiths, HR1
Wang, DD1
Yu, LP1
Wu, MN1
Sun, LN1
Qi, JS1
Lauterbach, EC1
Victoroff, J1
Coburn, KL1
Shillcutt, SD1
Doonan, SM1
Mendez, MF1
Kornhuber, J1
Tripal, P1
Reichel, M1
Mühle, C1
Rhein, C1
Muehlbacher, M1
Groemer, TW1
Gulbins, E1
Francis, BM1
Yang, J1
Hajderi, E1
Brown, ME1
Michalski, B1
McLaurin, J1
Fahnestock, M1
Mount, HT1
Odenheimer, GL1

Reviews

3 reviews available for desipramine and Acute Confusional Senile Dementia

ArticleYear
Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data.
    The Journal of neuropsychiatry and clinical neurosciences, 2010,Winter, Volume: 22, Issue:1

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Antipsychotic Agents; Benzodiazepines; Benzo

2010
Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2010, Volume: 26, Issue:1

    Topics: Acid Ceramidase; Alzheimer Disease; Clinical Trials as Topic; Desipramine; Humans; Phosphodiesterase

2010
Management of patients with Alzheimer's disease.
    Pharmacotherapy, 1991, Volume: 11, Issue:3

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents; Causality; Desipramine; Electroco

1991

Trials

1 trial available for desipramine and Acute Confusional Senile Dementia

ArticleYear
Comparison of sertraline, venlafaxine and desipramine effects on depression, cognition and the daily living activities in Alzheimer patients.
    Pharmacopsychiatry, 2014, Volume: 47, Issue:4-5

    Topics: Activities of Daily Living; Aged; Alzheimer Disease; Antidepressive Agents; Cognition; Comorbidity;

2014

Other Studies

29 other studies available for desipramine and Acute Confusional Senile Dementia

ArticleYear
9-Amino-1,2,3,4-tetrahydroacridin-1-ols: synthesis and evaluation as potential Alzheimer's disease therapeutics.
    Journal of medicinal chemistry, 1989, Volume: 32, Issue:8

    Topics: Alzheimer Disease; Aminoacridines; Animals; Chemical Phenomena; Chemistry; Cholinesterase Inhibitors

1989
Novel tacrine analogues for potential use against Alzheimer's disease: potent and selective acetylcholinesterase inhibitors and 5-HT uptake inhibitors.
    Journal of medicinal chemistry, 1997, Oct-24, Volume: 40, Issue:22

    Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Humans; Magnetic Resonance Spect

1997
Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease.
    Journal of medicinal chemistry, 2009, May-14, Volume: 52, Issue:9

    Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Blood-Brain Barrier; Butyrylcholines

2009
Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
    Journal of medicinal chemistry, 2009, Sep-10, Volume: 52, Issue:17

    Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases

2009
Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease.
    Journal of medicinal chemistry, 2009, Nov-26, Volume: 52, Issue:22

    Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cataly

2009
N-acylaminophenothiazines: neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:6

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Antineoplastic Agents; Butyrylcholinesterase; Calcium; Cel

2011
Hybrids of oxoisoaporphine-tacrine congeners: novel acetylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation inhibitors.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:10

    Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Aporphines; Blood-

2011
A small chemical library of 2-aminoimidazole derivatives as BACE-1 inhibitors: Structure-based design, synthesis, and biological evaluation.
    European journal of medicinal chemistry, 2012, Volume: 48

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Cell Surviv

2012
Novel oxoisoaporphine-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.
    Bioorganic & medicinal chemistry letters, 2012, Mar-15, Volume: 22, Issue:6

    Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Aporphines; Binding Sites; Blood-Bra

2012
Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids.
    Bioorganic & medicinal chemistry, 2013, Dec-01, Volume: 21, Issue:23

    Topics: Alzheimer Disease; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; Cholinesterases; Electro

2013
Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting β-amyloid, tau, and cholinesterase pathologies.
    European journal of medicinal chemistry, 2014, Sep-12, Volume: 84

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Cholinesterases; Dose-Response

2014
Discovery of indanone derivatives as multi-target-directed ligands against Alzheimer's disease.
    European journal of medicinal chemistry, 2014, Nov-24, Volume: 87

    Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; B

2014
In Vitro Inhibitory Effects of 8-O-Demethylmaritidine and Undulatine on Acetylcholinesterase and Their Predicted Penetration across the Blood-Brain Barrier.
    Journal of natural products, 2015, Jun-26, Volume: 78, Issue:6

    Topics: Acetylcholinesterase; Alzheimer Disease; Amaryllidaceae Alkaloids; Biological Transport; Blood-Brain

2015
Development of Multifunctional Pyrimidinylthiourea Derivatives as Potential Anti-Alzheimer Agents.
    Journal of medicinal chemistry, 2016, Sep-22, Volume: 59, Issue:18

    Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Cell Line; Ch

2016
Synthesis and evaluation of 8-hydroxyquinolin derivatives substituted with (benzo[d][1,2]selenazol-3(2H)-one) as effective inhibitor of metal-induced Aβ aggregation and antioxidant.
    Bioorganic & medicinal chemistry, 2016, 10-01, Volume: 24, Issue:19

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Copper; Drug Design; Hu

2016
Multitarget-directed oxoisoaporphine derivatives: Anti-acetylcholinesterase, anti-β-amyloid aggregation and enhanced autophagy activity against Alzheimer's disease.
    Bioorganic & medicinal chemistry, 2016, 11-15, Volume: 24, Issue:22

    Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Aporphines; Autophagy; Cholinesteras

2016
Design, synthesis and evaluation of 2-arylethenyl-N-methylquinolinium derivatives as effective multifunctional agents for Alzheimer's disease treatment.
    European journal of medicinal chemistry, 2017, Apr-21, Volume: 130

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Cell Death; Cell Line;

2017
Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia.
    European journal of medicinal chemistry, 2017, Apr-21, Volume: 130

    Topics: Alzheimer Disease; Animals; Brain Ischemia; Calcium Channel Blockers; Cholinesterase Inhibitors; Don

2017
The concept of hybrid molecules of tacrine and benzyl quinolone carboxylic acid (BQCA) as multifunctional agents for Alzheimer's disease.
    European journal of medicinal chemistry, 2018, Apr-25, Volume: 150

    Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cell Line; Cholinesterase I

2018
Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors.
    European journal of medicinal chemistry, 2018, Oct-05, Volume: 158

    Topics: Alzheimer Disease; Blood-Brain Barrier; Cholinesterase Inhibitors; Cholinesterases; Chromones; Drug

2018
Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.
    European journal of medicinal chemistry, 2019, Feb-01, Volume: 163

    Topics: Alzheimer Disease; Aminopyridines; Animals; Benzamides; Clioquinol; Cyclic Nucleotide Phosphodiester

2019
A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors.
    European journal of medicinal chemistry, 2019, Oct-15, Volume: 180

    Topics: Acetylcholinesterase; Adamantane; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitor

2019
Rational design and biological evaluation of a new class of thiazolopyridyl tetrahydroacridines as cholinesterase and GSK-3 dual inhibitors for Alzheimer's disease.
    European journal of medicinal chemistry, 2020, Dec-01, Volume: 207

    Topics: Acetylcholinesterase; Acridines; Alzheimer Disease; Animals; Blood-Brain Barrier; Cholinesterase Inh

2020
Discovery of potent glycogen synthase kinase 3/cholinesterase inhibitors with neuroprotection as potential therapeutic agent for Alzheimer's disease.
    Bioorganic & medicinal chemistry, 2021, 01-15, Volume: 30

    Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug

2021
The novel therapeutic strategy of vilazodone-donepezil chimeras as potent triple-target ligands for the potential treatment of Alzheimer's disease with comorbid depression.
    European journal of medicinal chemistry, 2022, Feb-05, Volume: 229

    Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antidepressive Agents; Binding Sites; Brain; Choli

2022
Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
    European journal of medicinal chemistry, 2022, Jun-05, Volume: 236

    Topics: Alzheimer Disease; Animals; Caenorhabditis elegans; Disease Models, Animal; Memantine; Mice; Recepto

2022
Oxidized LDL lipids increase β-amyloid production by SH-SY5Y cells through glutathione depletion and lipid raft formation.
    Free radical biology & medicine, 2014, Volume: 75

    Topics: Acetylcysteine; Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor

2014
Desipramine improves depression-like behavior and working memory by up-regulating p-CREB in Alzheimer's disease associated mice.
    Journal of integrative neuroscience, 2016, Volume: 15, Issue:2

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antidepressive Agents, Tricyclic; Cyclic AMP Resp

2016
Reduced tissue levels of noradrenaline are associated with behavioral phenotypes of the TgCRND8 mouse model of Alzheimer's disease.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2012, Volume: 37, Issue:8

    Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic Uptake Inhibitors; Aging; Alzheimer Disease; Amy

2012